Mutation-counting blood test could predict if cutting-edge immunotherapies can beat a cancer

Some cancers generate the seeds of their own destruction. Certain random mutations that accumulate in rapidly dividing tumor cells can spur the immune system to attack the cancer. Researchers are now learning that the extent of such mutations can predict whether a cancer will respond to new, powerful, immune-based therapies. A recently unveiled blood test for this so-called tumor mutational burden (TMB) could help make it a practical tool for guiding cancer treatment. Read more.

ca_0629NID_T_Lymphocytes_Cancer_online

Author: Dr. Baek

- Scientist (Microbiology, Synthetic Biology, Molecular Biology). - Founder / CEO of the biotech company Peption LLC. - Passionate about biotechnological innovations to address important global health issues.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s